These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24180627)

  • 21. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes.
    Sebestyén MG; Wong SC; Trubetskoy V; Lewis DL; Wooddell CI
    Methods Mol Biol; 2015; 1218():163-86. PubMed ID: 25319651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.
    Marimani MD; Ely A; Buff MC; Bernhardt S; Engels JW; Scherman D; Escriou V; Arbuthnot P
    J Control Release; 2015 Jul; 209():198-206. PubMed ID: 25937322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration.
    Devoldere J; Peynshaert K; Dewitte H; Vanhove C; De Groef L; Moons L; Özcan SY; Dalkara D; De Smedt SC; Remaut K
    J Control Release; 2019 Aug; 307():315-330. PubMed ID: 31265881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of gene therapy for treatment of age-related macular degeneration.
    Askou AL
    Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.
    Guzman-Aranguez A; Loma P; Pintor J
    Br J Pharmacol; 2013 Oct; 170(4):730-47. PubMed ID: 23937539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
    Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
    Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The RNA-binding protein Musashi-1 is produced in the developing and adult mouse eye.
    Raji B; Dansault A; Leemput J; de la Houssaye G; Vieira V; Kobetz A; Arbogast L; Masson C; Menasche M; Abitbol M
    Mol Vis; 2007 Aug; 13():1412-27. PubMed ID: 17768378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of siRNAs in vitro and in vivo.
    Cheng A; Vlassov AV; Magdaleno S
    Methods Mol Biol; 2011; 764():183-97. PubMed ID: 21748641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment.
    Zahn G; Volk K; Lewis GP; Vossmeyer D; Stragies R; Heier JS; Daniel PE; Adamis AP; Chapin EA; Fisher SK; Holz FG; Löffler KU; Knolle J
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1028-35. PubMed ID: 19815730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of intravitreal bevacizumab in the developing rabbit retina.
    Zayit-Soudry S; Zemel E; Barak A; Perlman I; Loewenstein A
    Retina; 2011 Oct; 31(9):1885-95. PubMed ID: 21799464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific anti-viral effects of RNA interference on replication and expression of hepatitis B virus in mice.
    Wu Y; Huang AL; Tang N; Zhang BQ; Lu NF
    Chin Med J (Engl); 2005 Aug; 118(16):1351-6. PubMed ID: 16157029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNAi therapeutics: an update on delivery.
    Nguyen T; Menocal EM; Harborth J; Fruehauf JH
    Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles.
    Elfakess R; Peer D
    IDrugs; 2010 Sep; 13(9):626-31. PubMed ID: 20799145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.
    Gu L; Chen H; Tuo J; Gao X; Chen L
    Exp Eye Res; 2010 Sep; 91(3):433-9. PubMed ID: 20599960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model.
    Liu HA; Liu YL; Ma ZZ; Wang JC; Zhang Q
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4789-94. PubMed ID: 21519028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization.
    Zuo L; Fan Y; Wang F; Gu Q; Xu X
    Curr Eye Res; 2010 May; 35(5):375-84. PubMed ID: 20450250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.
    Lee NS; Dohjima T; Bauer G; Li H; Li MJ; Ehsani A; Salvaterra P; Rossi J
    Nat Biotechnol; 2002 May; 20(5):500-5. PubMed ID: 11981565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.